𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinically relevant differences in the Model for End-Stage Liver Disease and Model for End-Stage Liver Disease–sodium scores

✍ Scribed by Rhiana Garritsen; Andrei Tintu; Herold Metselaar; Geert Kazemier

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
38 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

With interest, we read the article by Xiol et al. 1 regarding differences in serum measurements between different laboratories and their influence on the Model for End-Stage Liver Disease (MELD) and the Model for End-Stage Liver Disease incorporating serum sodium (MELD-Na). They reported significant differences in serum bilirubin, creatinine, international normalized ratio, and serum sodium levels between different laboratories, which led to clinically relevant variations in MELD and MELD-Na scores.

We have some remarks regarding the methodology of this study. First, samples were distributed to 3 different laboratories at room temperature. To minimize sample degradation, the use of frozen samples is preferable.

Second, serum creatinine was measured with the Jaffe ´method. It is generally agreed that this method tends to overestimate serum creatinine levels and, more importantly, is highly sensitive to disturbances (eg, ascorbine acid, uric acid, glucose, and several antibiotics). 2,3 Therefore, it is not the best test for the analysis of serum creatinine, particularly in this setting. Enzymatic measurements are more reliable and therefore should have been preferred. 3 Third, in the study by Xiol et al., 1 indirect potentiometry was used for the measurement of serum sodium. In our center, a similar test is used for this analysis, with a variation coefficient of 0.7%. In the Netherlands, a variation between centers and the national average of Ͻ1% is accepted. Surprisingly, in this study, a variation of 3% was found between center A and centers B and C. We wonder if there could be a methodological calibration error at center A that could explain this difference.

📜 SIMILAR VOLUMES

Reply: Clinically relevant differences i
Reply: Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores
✍ Xavier Xiol; Jose Castellote; Xavier Fuentes-Arderiu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 1 views

We thank Garritsen et al. 1 for their interest in our article about differences in Model for End-Stage Liver Disease (MELD) and Model for End-Stage Liver Disease-Sodium (MELD-Na) scores determined at 3 different laboratories. 2 We agree that one of the important messages of our article is the import

Clinically relevant differences in the m
Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores determined at three university-based laboratories of the same area
✍ Xavier Xiol; Pere Gines; Lluis Castells; Jorge Twose; Alba Ribalta; Xavier Fuent 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

The Model for End-Stage Liver Disease (MELD) score is considered an objective and reliable measure of liver disease severity. However, the use of specific laboratory methodologies may introduce significant and clinically relevant variations into the score. It has been suggested that the incorporatio

The model for end-stage liver disease (M
The model for end-stage liver disease (MELD)
✍ Patrick S. Kamath; W. Ray Kim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 1 views

The Model for End-stage Liver Disease (MELD) was initially created to predict survival in patients with complications of portal hypertension undergoing elective placement of transjugular intrahepatic portosystemic shunts. The MELD which uses only objective variables was validated subsequently as an

Model for end-stage liver disease except
Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system
✍ Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific

Model for end-stage liver disease (MELD)
Model for end-stage liver disease (MELD) exception for polycystic liver disease
✍ Luis Arrazola; Dilip Moonka; Robert G. Gish; Gregory T. Everson 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Polycystic liver disease (PLD) is commonly associated with polycystic kidney disease, but is unaccompanied by renal cysts in 10% of cases. Symptomatic PLD is mainly limited to adults and rarely, if ever, presents in childhood. There is currently no effective medical therapy for PLD. Most patients wh